---
title: "CERO THERAPEUTICS HOLDINGS INC C/WTS 13/02/2029 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -1.59"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/240452331.md"
datetime: "2025-05-15T20:59:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/240452331.md)
  - [en](https://longbridge.com/en/news/240452331.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/240452331.md)
---

# CERO THERAPEUTICS HOLDINGS INC C/WTS 13/02/2029 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -1.59

EPS: As of FY2025 Q1, the actual value is USD -1.59.

### Segment Revenue

-   The company has not recognized any revenue from any sources, including from product sales, and does not expect to generate any revenue from the sale of products in the foreseeable future.

### Operational Metrics

-   **Net Loss**: For the three months ended March 31, 2025, net loss amounted to $5.1 million, compared to $2.3 million for the same period in 2024, representing an increase of $2.8 million or 122.0%.
-   **Research and Development Expenses**: R&D expenses were $2.9 million for the three months ended March 31, 2025, compared to $1.7 million for the same period in 2024, reflecting an increase of $1.2 million.
-   **General and Administrative Expenses**: General and administrative expenses were $2.0 million for the three months ended March 31, 2025, compared to $2.9 million for the same period in 2024, reflecting a decrease of approximately $0.8 million.

### Cash Flow

-   **Net Cash Used in Operating Activities**: For the three months ended March 31, 2025, net cash used in operating activities was $4.4 million, compared to $5.1 million for the same period in 2024.
-   **Net Cash Provided by Financing Activities**: For the three months ended March 31, 2025, net cash provided by financing activities was $6.3 million, compared to $7.2 million for the same period in 2024.

### Unique Metrics

-   **Preferred Stock**: As of March 31, 2025, the company had outstanding 1,429 shares of Series A Preferred Stock, 198 shares of Series B Preferred Stock, and 2,537 shares of Series C Preferred Stock.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to substantially increase its R&D expenses for the foreseeable future as it continues the development of its product candidates through clinical development.
-   **Going Concern**: The company anticipates that substantial additional funding will be needed in connection with its continuing operations. As of March 31, 2025, the company reported $5.1 million of cash and cash equivalents, with an accumulated deficit of $76.0 million.
-   **Recent Developments**: On April 21, 2025, the company entered into a Securities Purchase Agreement with certain investors for the purchase of up to 10,000 shares of Series D Preferred Stock for an aggregate purchase price of up to $8 million.

### Related Stocks

- [CEROW.US](https://longbridge.com/en/quote/CEROW.US.md)

## Related News & Research

- [IREN Just Passed Its Biggest AI Test as Microsoft and Nvidia Bet Billions](https://longbridge.com/en/news/296533962.md)
- [Why Iovance Biotherapeutics Stock Hit 52-Week High](https://longbridge.com/en/news/296522969.md)
- [Broadcom Stabilizes After Google's $120 Billion Marvell Shock](https://longbridge.com/en/news/296529317.md)
- [Nvidia Chip-Filled Data Centers Need More Power Than Any Utility Can Promise. Here's Who Actually Wins.](https://longbridge.com/en/news/296453760.md)
- [LIVE MARKETS-Rising AI-related debt issuance, widening tech CDS spreads: Is there a cliff up ahead?](https://longbridge.com/en/news/296519886.md)